Clinical Trials | January 01, 2026
SOFIE Biosciences doses first patient in Phase 3 trial of novel cancer imaging agent
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The study will run across 18 sites and enroll roughly 200 patients over 24 months
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
Applications include detailed scientific rationale and supporting clinical evidence
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The plant is expected to enhance regional supply capabilities
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
Harbour BioMed brings advanced antibody discovery platforms to the table
Subscribe To Our Newsletter & Stay Updated
